AR005274A1 - Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante. - Google Patents

Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante.

Info

Publication number
AR005274A1
AR005274A1 ARP960105889A ARP960105889A AR005274A1 AR 005274 A1 AR005274 A1 AR 005274A1 AR P960105889 A ARP960105889 A AR P960105889A AR P960105889 A ARP960105889 A AR P960105889A AR 005274 A1 AR005274 A1 AR 005274A1
Authority
AR
Argentina
Prior art keywords
polypeptides
hydrophobic
isoleucyl
valine
isoleucine
Prior art date
Application number
ARP960105889A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18302038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR005274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR005274A1 publication Critical patent/AR005274A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Abstract

Una composición seca que comprende por lo menos uno de los ingredientes activos seleccionados del grupo que consiste en proteínas farmacológicamenteactivas y polipéptidos farmacológicamente activos y como estabilizante, por lo menos uno de lose stabilizantes hidrófobos seleccionados del grupo que consisteen aminoácidos hidrófobos, dipéptidos hidrófobos y tripéptidos hidrófobos, que tengan un Indice de Hidropatía de por lo menos 3. Aún cuando se deje a lacomposición seca anteriormentemenci onada en un medio altamente húmedo, la misma retiene su estado seco durante un período prolongado, no se licua ydifícilmente pierde su actividad farmacológica. Los ejemplos de aminoácidos hidrófobos adecuados incluyen valina, leucina,isoleu cina o similares. Losejemplos de dipéptidos hidrófobos adecuados incluyen leucil-valina, isoleucil- valina, isoleucil-leucina, fenilalanil-isoleucina o similares. Los ejemplos detripéptidos hidrófobos adecuados incluyen isoleucil-leucil-valina, isol eucil- valil-fenilalanina, isoleucil-valil-isoleucina o similares.
ARP960105889A 1995-12-25 1996-12-26 Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante. AR005274A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33671495 1995-12-25

Publications (1)

Publication Number Publication Date
AR005274A1 true AR005274A1 (es) 1999-04-28

Family

ID=18302038

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105889A AR005274A1 (es) 1995-12-25 1996-12-26 Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante.

Country Status (16)

Country Link
EP (2) EP0869816B1 (es)
JP (2) JP3208441B2 (es)
KR (1) KR100461291B1 (es)
CN (1) CN101279095A (es)
AR (1) AR005274A1 (es)
AT (2) ATE387188T1 (es)
AU (1) AU705094B2 (es)
BR (1) BR9612236A (es)
CA (1) CA2241179C (es)
DE (2) DE69634046T2 (es)
DK (2) DK0869816T3 (es)
ES (2) ES2300667T3 (es)
MX (1) MX9805196A (es)
PT (2) PT1424066E (es)
TW (1) TW403653B (es)
WO (1) WO1997023239A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2301889C (en) * 1998-06-26 2008-02-19 Otsuka Pharmaceutical Co., Ltd. Water-soluble dry compositions
ATE313318T1 (de) * 1999-10-29 2006-01-15 Nektar Therapeutics Trockenpulverzusammensetzungen mit verbesserter dispersität
CA2395438C (en) * 1999-12-24 2009-10-13 Otsuka Pharmaceutical Co., Ltd. Dry compositions containing hydrophobic amino acid
US7262317B2 (en) 2000-07-24 2007-08-28 Ono Pharmaceuticals Co., Ltd. Freeze-dried preparation of n[o-(p-pivaloyloxybenzenasulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing same
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
KR100815216B1 (ko) * 2001-06-15 2008-03-19 오츠카 세이야쿠 가부시키가이샤 경폐 투여용 건조 분말 흡입 시스템
BR0306741A (pt) 2002-02-22 2004-12-28 Ajinomoto Kk Método para produzir um pó de aminoácidos, e, pó de aminoácidos
WO2004028557A1 (ja) * 2002-09-26 2004-04-08 Shionogi & Co., Ltd. 安定化されたタンパク組成物
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
JPWO2006062238A1 (ja) * 2004-12-07 2008-06-12 味の素株式会社 アミノ酸の微粉末及びその懸濁液
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
JP5034944B2 (ja) * 2005-07-27 2012-09-26 味の素株式会社 インターフェロン作用物質の活性増強剤
EP2167686A1 (en) * 2007-06-16 2010-03-31 Enigma Diagnostics Ltd. Compositions
MX2016000739A (es) * 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CN104472877B (zh) * 2014-12-17 2017-07-18 宁夏伊品生物科技股份有限公司 L‑赖氨酸制品的制备工艺
WO2018113891A1 (en) * 2016-12-23 2018-06-28 University Of Copenhagen A co-amorphous form of a substance and a dipeptide
JP7149630B2 (ja) 2021-01-14 2022-10-07 株式会社G.A.Yellows 樹脂リム一体型金属眼鏡フレーム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ES2245780T3 (es) * 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent

Also Published As

Publication number Publication date
ES2300667T3 (es) 2008-06-16
ATE284713T1 (de) 2005-01-15
DE69634046D1 (de) 2005-01-20
JP4099623B2 (ja) 2008-06-11
JP2001172198A (ja) 2001-06-26
ATE387188T1 (de) 2008-03-15
EP0869816A1 (en) 1998-10-14
DK0869816T3 (da) 2005-01-31
KR19990076752A (ko) 1999-10-15
PT1424066E (pt) 2008-04-23
AU705094B2 (en) 1999-05-13
ES2233983T3 (es) 2005-06-16
MX9805196A (es) 1998-10-31
JP3208441B2 (ja) 2001-09-10
JPH09235238A (ja) 1997-09-09
EP0869816B1 (en) 2004-12-15
BR9612236A (pt) 1999-07-13
KR100461291B1 (ko) 2005-02-28
DE69637450D1 (de) 2008-04-10
CA2241179C (en) 2010-10-19
WO1997023239A1 (en) 1997-07-03
DE69634046T2 (de) 2005-12-22
AU1173297A (en) 1997-07-17
DK1424066T3 (da) 2008-05-26
CN101279095A (zh) 2008-10-08
EP1424066A1 (en) 2004-06-02
TW403653B (en) 2000-09-01
DE69637450T2 (de) 2009-02-19
PT869816E (pt) 2005-03-31
CA2241179A1 (en) 1997-07-03
EP1424066B1 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
AR005274A1 (es) Una composición seca que comprende por lo menos un ingrediente activo seleccionado entre enzimas, inmunoglobulinas, polipéptidos antivirales, polipéptidos inmunorregulatorios y polipéptidos hematopoiéticos y por lo menos un estabilizante.
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
IT1200589B (it) Derivati naturali attivita farmagologica
BR0313970A (pt) Composições pesticidas contendo ácidos dicarboxìlicos
WO2006103037A3 (de) ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2
PT758018E (pt) Preparacoes de enzimas estabilizadas com um sal
SE9504077L (sv) Absorberande artikel såsom en blöja med en skålformig absorpstionskropp uppvisande minst en urtagning i form av spår eller kompressionslinjer
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
AR017416A1 (es) Composicion detergente adecuada para ser usada en el lavado de vajilla y estabilizador de espuma proteinaceo
CA2139725A1 (en) Endoparasiticidal compositions
ES2153112T3 (es) Composiciones dispersables en agua secas de plaguicidas microencapsulados.
CA2256410A1 (en) Stable pharmaceutical composition of bdnf
PE20011283A1 (es) Articulos absorbentes que comprenden material de quitosana y un material gelificante absorbente anionico
PT830130E (pt) Enzima de conversao de tnf-alfa
ES2119161T3 (es) Soluciones de dialisis peritoneal mejoradas que incluyen polipeptidos.
ES2058479T3 (es) Compuestos peptidicos.
WO2001025390A3 (en) Water unstable foam compositions
BR0014498A (pt) Artigos elásticos e uso dos mesmos
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
BR9912166A (pt) Uso de dióxido de carbono e ácido carbÈnico para limpeza de lentes de contato
CA2047802A1 (en) Pharmaceutical compositions
GB1533077A (en) 4-substituted enkephalin derivatives
ES2174481T3 (es) Empleo de soluciones que contienen enzimas para la limpieza de tanques de fermentacion o de almacenamiento.
DE59908481D1 (de) Wasch- und reinigungsmittelformkörper/verpackung-kombination

Legal Events

Date Code Title Description
FG Grant, registration